Should I Buy CGEN? CGEN 2026 Analysis

Should You Buy Compugen Ltd (CGEN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.670

1 Day change

5.03%

52 Week Range

2.660

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: price is sitting on/just below a key support (S1 ~1.824) with bearish momentum still expanding (MACD histogram negative and worsening).
Without Intellectia signals (no AI Stock Picker, no SwingMax), there’s no strong edge to justify chasing a pre-market entry today.
Options positioning looks structurally bullish (calls dominate open interest), but there’s effectively no options volume today, so it’s not a strong real-time sentiment confirmation.
Financial trend in the latest quarter (2025/Q3) deteriorated sharply YoY (revenue and margins down; losses larger), which weakens the fundamental backdrop into the next earnings catalyst.

Technical Analysis

Trend/Momentum: Bearish near-term; MACD histogram at -0.0431 and negatively expanding suggests downside momentum is strengthening.
RSI: RSI_6 ~30.16 (near oversold). This can support a bounce attempt, but it’s not a reversal confirmation by itself while MACD worsens.
Moving averages: Converging MAs = no clear bullish trend; consistent with a choppy-to-weak tape.
Levels that matter now: Price 1.82 is essentially at S1 (1.824). A clean loss of this area increases risk of probing S2 (1.724). Upside needs reclaim of the pivot (1.986) first, then R1 (2.149).
Pattern-based forward odds: Similar-pattern stats imply ~60% chance of modest downside over the next day/week (-1.63% / -2.66%), despite a more favorable 1-month expectation (+10.2%).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Put/call OI ratio 0.07 indicates heavy call open interest vs puts (call OI 12,381 vs put OI 910) — a bullish-leaning structure.
Activity: Today’s options volume is 0, so there’s no live confirmation of bullishness from current flow.
Volatility: Very high implied volatility (30D IV ~182.88; IV percentile ~76.4) suggests the market is pricing large moves (common in small-cap biotech), but direction is not confirmed by volume today.
Takeaway: Sentiment via open interest skews bullish, but lack of volume + bearish technical momentum reduces confidence for an immediate buy.

Technical Summary

Sell

Buy

Positive Catalysts

and triggers momentum buying.

Neutral/Negative Catalysts

showed severe YoY deterioration across revenue, margins, and profitability, which can weigh on sentiment until clearer pipeline/partner monetization traction appears.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: 1.891M, down -88.96% YoY (sharp contraction).
Profitability: Net income -6.979M, down -646.94% YoY (loss widened materially).
EPS: -0.07, down -800.00% YoY.
Gross margin: 12.74%, down -83.87% YoY.
Summary: Growth and margin trends are currently negative, making the stock more catalyst-driven than fundamentals-driven in the near term.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent change: On 2026-01-07, H.C. Wainwright initiated coverage at Buy with a $4 price target.
What Wall Street “pros” like: Multi-shot immuno-oncology pipeline and potential royalty stream economics referenced by the analyst.
Key Wall Street “cons” from the data at hand: Limited breadth of recent coverage/updates provided here and weak recent financial trend (2025/Q3) increases reliance on future pipeline/partner catalysts.
Net view: Analyst commentary is bullish on long-term upside, but near-term trading setup is not compelling without a technical turn or proprietary signal.

3 Analyst Rating

Wall Street analysts forecast CGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGEN is 4 USD with a low forecast of 4 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.590

Low

Averages

High

Current: 1.590

Low

Averages

High

H.C. Wainwright

NULL -> Buy

initiated

AI Analysis

2026-01-07

Reason